PTC Therapeutics, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Leads in Yearly Revenue?

PTC Therapeutics dominates revenue growth over Arrowhead Pharmaceuticals.

__timestampArrowhead Pharmaceuticals, Inc.PTC Therapeutics, Inc.
Wednesday, January 1, 201417500022963000
Thursday, January 1, 201538200036766000
Friday, January 1, 201615833382705000
Sunday, January 1, 201731407709194392000
Monday, January 1, 201816142321264734000
Tuesday, January 1, 2019168795577306980000
Wednesday, January 1, 202087992066380766000
Friday, January 1, 2021138287000538593000
Saturday, January 1, 2022243231000698801000
Sunday, January 1, 2023240735000937822000
Monday, January 1, 20243551000
Loading chart...

Infusing magic into the data realm

PTC Therapeutics vs. Arrowhead Pharmaceuticals: A Revenue Showdown

In the competitive landscape of biotechnology, revenue growth is a key indicator of success. Over the past decade, PTC Therapeutics, Inc. has consistently outperformed Arrowhead Pharmaceuticals, Inc. in terms of annual revenue. Starting in 2014, PTC Therapeutics generated nearly 13 times more revenue than Arrowhead, and this trend has continued. By 2023, PTC's revenue surged to approximately 938 million, marking a staggering 3,900% increase from 2014. In contrast, Arrowhead's revenue, while growing, reached around 241 million in 2023, reflecting a significant but smaller growth rate of about 137,000% from its 2014 figures. This data highlights PTC Therapeutics' robust market presence and strategic growth initiatives. However, Arrowhead's recent revenue uptick suggests potential for future competition. As the biotech industry evolves, these companies' financial trajectories will be crucial for investors and stakeholders alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025